Stock events for Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals' stock has been impacted by several key events in the past six months. The company reported its third-quarter 2025 financial results on November 5, 2025, with Rezdiffra net sales of $287.3 million, exceeding analyst estimates, which led to a 7.8% gain in MDGL shares. By September 30, 2025, over 29,500 patients were on Rezdiffra. A significant development was the closing of a global licensing agreement with CSPC Pharma to add an oral GLP-1 to its pipeline and the securing of a new Orange Book listed patent for Rezdiffra, extending protection into 2045. The European Commission approved Rezdiffra in August 2025, and the drug began selling in Germany in September 2025, expanding its market. On February 19, 2026, Madrigal Pharmaceuticals reported its fourth-quarter and full-year 2025 financial results. While full-year 2025 net sales reached $958.4 million and Q4 2025 net sales were $321.1 million, beating revenue estimates, the company posted a wider-than-expected Q4 loss of $2.57 per share, missing analyst forecasts. This mixed report led to an approximate 8% decline in the stock price in premarket trading and an 11.11% decline on the day of the announcement. As of March 3, 2026, the share price was $425.85, representing a 32.53% increase over the previous year.
Demand Seasonality affecting Madrigal Pharmaceuticals, Inc.’s stock price
There have been observations of demand seasonality for Madrigal Pharmaceuticals' products, specifically Rezdiffra. Seasonal reimbursement issues have led to temporary fluctuations in the number of patients on paid drug, particularly during the first quarter of the year. This suggests that while overall demand for the drug may be strong, the actual number of patients receiving paid treatment can vary throughout the year due to factors related to insurance and reimbursement cycles.
Overview of Madrigal Pharmaceuticals, Inc.’s business
Madrigal Pharmaceuticals specializes in the research, development, and commercialization of innovative drugs for metabolic and liver diseases, with its core business centered on metabolic and liver diseases. Its flagship product is Rezdiffra (resmetirom), the first FDA-approved medication for MASH with moderate to advanced liver fibrosis, to be used in conjunction with diet and exercise. The company is also evaluating Rezdiffra in an ongoing Phase 3 outcomes trial for the treatment of MASH with compensated cirrhosis.
MDGL’s Geographic footprint
Madrigal Pharmaceuticals is headquartered in Conshohocken, Pennsylvania, USA, which serves as its central hub for corporate operations, strategic planning, and research activities. The company's primary market and operational focus are in the United States, where it conducts most of its clinical trials, research, and commercialization efforts. Madrigal Pharmaceuticals has a limited international presence, with a minimal operational footprint in Europe, though it launched Rezdiffra in Germany following European Commission approval. It also has an emerging presence in the Asia-Pacific region, primarily through partnerships and clinical trial collaborations, exploring opportunities in markets such as Japan and Australia.
MDGL Corporate Image Assessment
Madrigal Pharmaceuticals has generally maintained a positive brand reputation over the past year, largely driven by the successful launch and strong market acceptance of Rezdiffra. The drug's FDA approval in March 2024 as the first therapy for MASH has positioned Madrigal as a key player in addressing a significant unmet medical need. Prescription rates for Rezdiffra have steadily increased, and a majority of doctors expect patients to remain on the drug for at least one year, indicating confidence in its long-term efficacy. However, the company's reputation and outlook have also faced scrutiny due to increasing competition from GLP-1 class drugs, such as Novo Nordisk's Wegovy, which also received FDA approval for MASH in late 2025. Additionally, a "Sell" rating from Zacks Investment Research in February 2026, despite strong revenue growth, indicated concerns about profitability and overall business performance, which could impact investor sentiment and, by extension, brand perception.
Ownership
Madrigal Pharmaceuticals has a highly concentrated ownership structure, with institutional investors holding a significant portion of the shares. As of March 5, 2026, there are 468 institutional owners and shareholders holding a total of 23,916,279 shares. Major institutional shareholders include Baker Bros. Advisors Lp, Rtw Investments, Lp, Vanguard Group Inc, Avoro Capital Advisors LLC, Paulson & Co. Inc., BlackRock, Inc., Janus Henderson Group Plc, State Street Corp, Wellington Management Group Llp, and Geode Capital Management, Llc. Individual ownership is also notable, with Bruce Kovner being the largest individual shareholder, owning 22.94 million shares, representing 99.99% of the company. Institutional shareholders account for 102.60% of the stock, while Madrigal Pharmaceuticals insiders hold 290.05%, and retail investors hold 0.00%.
